John Overdeck Two Sigma Investments
John Overdeck is a co-founder of Two Sigma Investments, one of the world’s leading quantitative and technology-driven investment firms. Two Sigma applies data science, machine learning, and large-scale computing to markets across asset classes. Overdeck’s firm is a central reference point in discussions of modern systematic investing.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$257M |
| 2 |
Boston Scientific
BSX
|
+$228M |
| 3 |
Meta Platforms (Facebook)
META
|
+$225M |
| 4 |
Amazon
AMZN
|
+$220M |
| 5 |
S&P Global
SPGI
|
+$219M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$252M |
| 2 |
PayPal
PYPL
|
+$252M |
| 3 |
Walt Disney
DIS
|
+$217M |
| 4 |
Chevron
CVX
|
+$206M |
| 5 |
Best Buy
BBY
|
+$152M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.83% |
| 2 | Consumer Discretionary | 13.53% |
| 3 | Financials | 9.1% |
| 4 | Healthcare | 9.07% |
| 5 | Consumer Staples | 8.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MDLA
3051
CALL
DELISTED
Medallia, Inc.
MDLA
| $226K | ﹤0.01% |
+6,800
| New | +$217K |
|
|
YELL
3052
DELISTED
Yellow Corporation Common Stock
YELL
| $226K | ﹤0.01% |
+50,921
| New | +$247K |
|
3053
PUT
Elevance Health
ELV
$87.3B
| $225K | ﹤0.01% |
700
-300
| -30% | -$92.1K |
|
3054
PUT
Huntington Bancshares
HBAN
$34.4B
| $225K | ﹤0.01% |
17,800
-4,100
| -19% | -$46.6K |
|
|
JHG
3055
DELISTED
Janus Henderson
JHG
| $225K | ﹤0.01% |
6,932
-180,538
| -96% | -$5.15M |
|
3056
CALL
Perrigo
PRGO
$1.98B
| $224K | ﹤0.01% |
+5,000
| New | +$232K |
|
3057
Jakks Pacific
JAKK
$292M
| $223K | ﹤0.01% |
+44,865
| New | +$212K |
|
3058
PUT
New York Times
NYT
$10.9B
| $223K | ﹤0.01% |
+4,300
| New | +$191K |
|
3059
Mammoth Energy Services
TUSK
$150M
| $223K | ﹤0.01% |
+50,215
| New | +$122K |
|
3060
Winmark
WINA
$1.26B
| $223K | ﹤0.01% |
1,200
-1,417
| -54% | -$252K |
|
|
ASAP
3061
DELISTED
Waitr Holdings Inc. Common Stock
ASAP
| $223K | ﹤0.01% |
4,003
+2,840
| +244% | +$183K |
|
3062
Caleres
CAL
$459M
| $222K | ﹤0.01% |
14,215
-28,500
| -67% | -$319K |
|
3063
CALL
Danaher
DHR
$151B
| $222K | ﹤0.01% |
+1,128
| New | +$226K |
|
3064
PUT
Flowserve
FLS
$10.2B
| $221K | ﹤0.01% |
+6,000
| New | +$196K |
|
3065
IES Holdings
IESC
$12.9B
| $221K | ﹤0.01% |
+9,600
| New | +$188K |
|
|
SGI
3066
PUT
Somnigroup International
SGI
$13.5B
| $221K | ﹤0.01% |
8,200
-6,600
| -45% | -$161K |
|
3067
Green Plains
GPRE
$1.05B
| $220K | ﹤0.01% |
16,685
-22,403
| -57% | -$341K |
|
3068
VirnetX Holding Corp
VHC
$52.1M
| $220K | ﹤0.01% |
+2,180
| New | +$236K |
|
3069
Inogen
INGN
$146M
| $219K | ﹤0.01% |
4,900
-116,113
| -96% | -$4.01M |
|
|
KG
3070
Kestrel Group
KG
$61.2M
| $219K | ﹤0.01% |
4,404
-131
| -3% | -$4.5K |
|
|
NAVB
3071
DELISTED
Navidea Biopharmaceuticals Inc.
NAVB
| $219K | ﹤0.01% |
101,949
+36,860
| +57% | +$86.9K |
|
3072
CALL
Conagra Brands
CAG
$8B
| $218K | ﹤0.01% |
6,000
-1,800
| -23% | -$65.3K |
|
3073
CALL
Cooper Companies
COO
$14.8B
| $218K | ﹤0.01% |
+2,400
| New | +$206K |
|
3074
Escalade
ESCA
$289M
| $218K | ﹤0.01% |
+10,307
| New | +$211K |
|
3075
CALL
Rithm Capital
RITM
$5.72B
| $218K | ﹤0.01% |
21,900
-26,400
| -55% | -$233K |
|
Similar funds
John Overdeck's Q4 2020 Portfolio in Review
As of Q4 2020, John Overdeck held 3,971 positions worth $34.9B, up 24% from $28.2B the previous quarter. Its ten largest holdings account for 7.4% of the portfolio.
John Overdeck deployed $1.95B of net new capital in Q4 2020, opening 955 new positions and adding to 1,167 existing holdings. Its largest new stake was Boston Scientific: 6,312,819 shares worth $227M.
By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 15% a quarter earlier, followed by Consumer Discretionary and Financials.
On the sell side, the largest reduction was Chevron, an estimated $206M trimmed.
- John Overdeck's largest Q4 2020 buy was Boston Scientific: 6,312,819 shares worth $227M.
- John Overdeck added most to NVIDIA in Q4 2020, an estimated $257M increase.
- John Overdeck's biggest Q4 2020 reduction was Chevron, cutting an estimated $206M.
- John Overdeck fully exited Pfizer in Q4 2020, selling an estimated $252M.
- John Overdeck's ten largest holdings make up 7.4% of its $34.9B portfolio in Q4 2020.
- John Overdeck opened 955 new positions and closed 694 in Q4 2020.
- John Overdeck's portfolio value rose 24% quarter-over-quarter to $34.9B.
Based on Two Sigma Investments's 13F filing for Q4 2020, filed 16 Feb 2021.